tiodazosin: BL 5111A is for mono-HCl; RN given refers to parent cpd; structure in third source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 60891 |
| CHEMBL ID | 2107039 |
| CHEBI ID | 177685 |
| SCHEMBL ID | 121554 |
| MeSH ID | M0072131 |
| Synonym |
|---|
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(5-methylsulanyl-1,3,4-oxadiazol-2-yl)methanone |
| CHEBI:177685 |
| tiodazosin |
| tiodazosin (usan/inn) |
| D06154 |
| 66969-81-1 |
| OPREA1_125434 |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(5-methylsulfanyl-1,3,4-oxadiazol-2-yl)methanone |
| CHEMBL2107039 |
| 2-(4-((5-methylthio-1,3,4-oxadiazol-2-yl)carbonyl)piperazino)-6,7-dimethoxy-4-chinazolinamin |
| tiodazosina [inn-spanish] |
| unii-fqi0pyj799 |
| tiodazosine |
| bl-5111 |
| tiodazosinum |
| piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((5-(methylthio)-1,3,4-oxadiazol-2-yl)carbonyl)- |
| fqi0pyj799 , |
| bl 5111 |
| tiodazosin [usan:inn] |
| tiodazosine [inn-french] |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((5-(methylthio)-1,3,4-oxadiazol-2-yl)carbonyl)-piperazine |
| tiodazosina |
| tiodazosinum [inn-latin] |
| SCHEMBL121554 |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[[5-(methylthio)-1,3,4-oxadiazol-2-yl]carbonyl]-piperazine |
| tiodazosin [usan] |
| tiodazosin [inn] |
| MULPYFRDYRZMDS-UHFFFAOYSA-N |
| 4-amino-6,7-dimethoxy-2-[4-(5-methylthio-1,3,4-oxadiazole-2-carbonyl)-piperazin-1-yl]quinazoline |
| DTXSID90217180 |
| HY-100255 |
| CS-0018406 |
| Q15634026 |
| (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(5-(methylthio)-1,3,4-oxadiazol-2-yl)methanone |
| AKOS040740402 |
Tiodazosin (BL5111) is a structural analogue of prazosin. It is currently being evaluated for clinical efficacy in the treatment of hypertension.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tiodazosin (BL5111) is a structural analogue of prazosin that is currently being evaluated for clinical efficacy in the treatment of hypertension. " | ( In vitro comparison of the pre- and postsynaptic alpha adrenergic receptor blocking properties of prazosin and tiodazosin (BL5111). Cohen, ML; Landry, AS; Wiley, KS, 1980) | 1.92 |
| "Tiodazosin is a recently developed compound that is currently undergoing investigation for use in hypertension. " | ( The bioavailability and disposition of tiodazosin levulinate in beagle dogs with a comparison to prazosin hydrochloride. Baughman, RA; Benet, LZ; Mico, BA, ) | 1.84 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Lacking an intravenous dosage form for use in human subjects, our study concentrated on the determination of the bioavailability and disposition parameters of tiodazosin in dogs, with a comparison to those parameters for prazosin, obtained from previous work in our laboratory." | ( The bioavailability and disposition of tiodazosin levulinate in beagle dogs with a comparison to prazosin hydrochloride. Baughman, RA; Benet, LZ; Mico, BA, ) | 0.6 |
Tiodazosin caused appreciably less alpha-adrenergic receptor antagonist activity than prazosin as assessed by the norepinephrine dose-pressor response profiles.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In contrast, BL-5111, an antihypertensive agent similar in chemical structure and shown in previous studies to be slightly less potent than prazosin but with appreciably less alpha-adrenergic receptor antagonist activity, had no effect on blood pressure at 12 hours after dosing (1 and 2 mg/kg po)." | ( Comparative first dose effects of prazosin and tiodazosin (BL-5111) in spontaneously hypertensive rats. Buyniski, JP; Florczyk, AP; Roebel, LE, 1979) | 0.52 |
| " Furthermore, at the end of the 52-day chronic dosing period tiodazosin caused appreciably less alpha-adrenergic receptor antagonist activity than prazosin as assessed by the norepinephrine dose-pressor response profiles." | ( Effects of tiodazosin, praxosin, trimazosin and phentolamine on blood pressure, heart rate and on pre- and postsynaptic alpha-adrenergic receptors in the rat. Buyniski, JP; Campbell, JA; Pircio, AW; Schurig, JE, 1980) | 0.89 |
| " Lacking an intravenous dosage form for use in human subjects, our study concentrated on the determination of the bioavailability and disposition parameters of tiodazosin in dogs, with a comparison to those parameters for prazosin, obtained from previous work in our laboratory." | ( The bioavailability and disposition of tiodazosin levulinate in beagle dogs with a comparison to prazosin hydrochloride. Baughman, RA; Benet, LZ; Mico, BA, ) | 0.6 |
| Class | Description |
|---|---|
| N-arylpiperazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (98.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||